Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Riederer

Showing results (531-540 of 587) with videos related to

Pageof 59
Sort By:
Neuroreport|March 7, 1995
Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in miceA Kupsch, M Gerlach, S C Pupeter, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 1, 1990
Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and in humans with schizophreniaM Schalling, K Friberg, K Seroogy, et al.
European Journal of Clinical Pharmacology|January 1, 1992
Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinuedH Przuntek, D Welzel, E Blümner, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 29, 2000
Naturally occurring benzodiazepines: current status of research and clinical implicationsP Sand, D Kavvadias, D Feineis, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|August 28, 1998
Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproductsG Münch, R Schinzel, C Loske, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|October 14, 2004
Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cellsM Shamoto-Nagai, W Maruyama, Y Akao, et al.
Journal of Alzheimer'S Disease : JAD|March 16, 2007
Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's diseaseC P Jacob, E Koutsilieri, J Bartl, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 1, 1996
Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO studyH Przuntek, D Welzel, M Gerlach, et al.
Molecular Psychiatry|April 28, 2001
Allelic variation of serotonin transporter expression is associated with depression in Parkinson's diseaseR Mössner, A Henneberg, A Schmitt, et al.
Alcohol and Alcoholism (Oxford, Oxfordshire)|January 5, 2001
Immunoreactivity of cAMP response element binding protein is not altered in the post-mortem cerebral cortex or cerebellum of alcoholicsM Yamamoto, S Pohli, N Durany, et al.
Pageof 59

Showing results (531-540 of 587) with videos related to

Sort By:
Pageof 59
Neuroreport|March 7, 1995
Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in miceA Kupsch, M Gerlach, S C Pupeter, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 1, 1990
Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and in humans with schizophreniaM Schalling, K Friberg, K Seroogy, et al.
European Journal of Clinical Pharmacology|January 1, 1992
Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinuedH Przuntek, D Welzel, E Blümner, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 29, 2000
Naturally occurring benzodiazepines: current status of research and clinical implicationsP Sand, D Kavvadias, D Feineis, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|August 28, 1998
Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproductsG Münch, R Schinzel, C Loske, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|October 14, 2004
Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cellsM Shamoto-Nagai, W Maruyama, Y Akao, et al.
Journal of Alzheimer'S Disease : JAD|March 16, 2007
Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's diseaseC P Jacob, E Koutsilieri, J Bartl, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 1, 1996
Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO studyH Przuntek, D Welzel, M Gerlach, et al.
Molecular Psychiatry|April 28, 2001
Allelic variation of serotonin transporter expression is associated with depression in Parkinson's diseaseR Mössner, A Henneberg, A Schmitt, et al.
Alcohol and Alcoholism (Oxford, Oxfordshire)|January 5, 2001
Immunoreactivity of cAMP response element binding protein is not altered in the post-mortem cerebral cortex or cerebellum of alcoholicsM Yamamoto, S Pohli, N Durany, et al.
Pageof 59